UNBELIEVABLE: 4 | History Defined

Jim Cramer Recommends These 4 Dividend Stocks, Says Era Of 'Magical Investing' In AI Is 'Dead'

CNBC host Jim Cramer has become more cautious toward AI and data center stocks after seeing increasing insider selling and borrowing activity. 

Benzinga · Nov 28, 2025

FDA poised to kill proposal that would require asbestos testing for cosmetics

RFK Jr signed order withdrawing rule that would mandate testing for the cancer-linked toxin in talc-based makeup

The Guardian - US · Nov 28, 2025

Is Johnson & Johnson Stock Outperforming the S&P 500?

Johnson & Johnson has outpaced the S&P 500 over the past year, and analysts remain optimistic about the healthcare stock's growth potential ahead.

Barchart · Nov 28, 2025

3 High-Growth Dividend Kings For Generations of Income - And Still Rated “Buy”

Dividend Kings with 20%+ YTD gains and strong analyst ratings show rare momentum, reliable income, and long-term stability across multiple sectors.

Barchart · Nov 15, 2025

The innovative new treatment which could help cancer patients avoid surgery

Bladder cancer is the ninth most common cancer in the world, the fourth most common cancer in men, and the 11th most common cancer in women

The Independent UK · Nov 14, 2025

FDA Clears Johnson & Johnson's Darzalex Faspro, Enabling Early Intervention In Myeloma Progression

The U.S. Food and Drug Administration (FDA) approved on Thursday Johnson Johnson’s (NYSE:JNJ) Darzalex Faspro (daratumumab and hyaluronidase-fihj) for a type of blood cancer.

Benzinga · Nov 7, 2025

Kimberly-Clark Snaps Up Tylenol Maker Kenvue in £30 Billion Takeover Amid Autism Controversy

Kimberly-Clark to acquire Kenvue, owner of Tylenol, in a £40 billion deal amid controversy over the painkiller's safety concerns and declining sales.

International Business Times UK · Nov 4, 2025

Kenvue Acquired by Kimberly-Clark in $48.7 Billion Deal to Form Consumer Staples Giant

Kimberly-Clark will acquire Kenvue in a $48.7 billion cash-and-stock deal, creating a new consumer health and personal care giant combining brands like Huggies, Kleenex, Johnson's Baby, and Band-Aid.

International Business Times UK · Nov 3, 2025

Johnson & Johnson Stock: Is Wall Street Bullish or Bearish?

Johnson & Johnson has delivered a standout performance in 2025, outperforming both the broader market and the healthcare sector. Analysts continue to be fairly bullish on the stock’s trajectory.

Barchart · Nov 3, 2025

The Only 3 Dividend Kings You’ll Ever Need for a Lifetime of Income

Three Dividend Kings with decades of dividend growth and strong financials are poised to deliver reliable income and stability for investors in 2025.

Barchart · Oct 31, 2025